ERS Publications Podcasts

As part of the October issue, the European Respiratory Journal presents the latest in its series of podcasts. Deputy Chief Editor James Chalmers interviews David Lederer (Editor-in-Chief, Annals of the American Thoracic Society) about the outcome of a recent discussion among respiratory journal editors on the reporting of causal inference studies.

As part of the September issue, the European Respiratory Journal presents the latest in its series of podcasts. Section Editor David Gozal interviews Walter McNicholas (St Vincent's University Hospital and University College Dublin, Ireland) about a report by an ad hoc working group of the Sleep Disordered Breathing Group of the European Respiratory Society and the European Sleep Research Society.

As part of the September issue, the European Respiratory Journal presents the latest in its series of podcasts. Section Editor David Gozal interviews Walter McNicholas (St Vincent's University Hospital and University College Dublin, Ireland) about a report by an ad hoc working group of the Sleep Disordered Breathing Group of the European Respiratory Society and the European Sleep Research Society.

As part of the September issue, the European Respiratory Journal presents the latest in its series of podcasts. Section Editor David Gozal interviews Walter McNicholas (St Vincent’s University Hospital and University College Dublin, Ireland) about a report by an ad hoc working group of the Sleep Disordered Breathing Group of the European Respiratory Society and the European Sleep Research Society.

As part of the May issue, the European Respiratory Journal presents the latest in its series of podcasts. Deputy chief editor James Chalmers interviews Marc Humbert (Université Paris-Sud, Faculté de Médecine, Université Paris-Saclay, and AP-HP, Service de Pneumologie, Hôpital Bicêtre, Le Kremlin-Bicêtre, and INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis Robinson, France) about omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count.

As part of the May issue, the European Respiratory Journal presents the latest in its series of podcasts. Deputy chief editor James Chalmers interviews Marc Humbert (Université Paris-Sud, Faculté de Médecine, Université Paris-Saclay, and AP-HP, Service de Pneumologie, Hôpital Bicêtre, Le Kremlin-Bicêtre, and INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis Robinson, France) about omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count.

As part of the May issue, the European Respiratory Journal presents the latest in its series of podcasts. Deputy chief editor James Chalmers interviews Marc Humbert (Université Paris-Sud, Faculté de Médecine, Université Paris-Saclay, and AP-HP, Service de Pneumologie, Hôpital Bicêtre, Le Kremlin-Bicêtre, and INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis Robinson, France) about omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count.

As part of the April issue, the European Respiratory Journal presents the latest in its series of podcasts. Chief editor Martin Kolb interviews Andreas von Leupoldt (University of Leuven, Belgium) and Thomas Similowski (Sorbonne Universités and Groupe Hospitalier Pitié-Salpêtrière Charles Foix, Paris, France) about how observing dyspnoea in others elicits dyspnoea, negative affect and brain responses.

As part of the April issue, the European Respiratory Journal presents the latest in its series of podcasts. Chief editor Martin Kolb interviews Andreas von Leupoldt (University of Leuven, Belgium) and Thomas Similowski (Sorbonne Universités and Groupe Hospitalier Pitié-Salpêtrière Charles Foix, Paris, France) about how observing dyspnoea in others elicits dyspnoea, negative affect and brain responses.

As part of the March issue, the European Respiratory Journal presents the latest in its series of podcasts. To mark World TB Day, chief editor Martin Kolb interviews section editor Giovanni Battista Migliori about the following articles.

Borisov SE, Dheda K, Enwerem M, et al. Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study. Eur Respir J 2017; 49: 1700387.

Cabibbe AM, Sotgiu G, Izco S, et al. Genotypic and phenotypic M. tuberculosis resistance: guiding clinicians to prescribe the correct regimens. Eur Respir J 2017; 50: 1702292.

Falzon D, Schünemann HJ, Harausz E, et al. World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update. Eur Respir J 2017; 49: 1602308.

Guglielmetti L, Jaspard M, Le Dû D, et al. Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis. Eur Respir J 2017; 49: 1601799.

Miotto P, Tessema B, Tagliani E, et al. A standardised method for interpreting the association between mutations and phenotypic drug resistance in Mycobacterium tuberculosis. Eur Respir J 2017; 50: 1701354.

Pontali E, Sotgiu G, Tiberi S, et al. Cardiac safety of bedaquiline: a systematic and critical analysis of the evidence. Eur Respir J 2017; 50: 1701462.

Van der Werf MJ, Hollo V, Ködmön C, et al. Eligibility for shorter treatment of multidrug-resistant tuberculosis in the European Union. Eur Respir J 2017; 49: 1601992.